| human | Q5 |
| P6178 | Dimensions author ID | 01224060130.78 |
| P496 | ORCID iD | 0000-0002-0322-4961 |
| P1153 | Scopus author ID | 12784913800 |
| P69 | educated at | University of Barcelona | Q219615 |
| P108 | employer | Institut Català de la Salut | Q11926710 |
| P106 | occupation | researcher | Q1650915 |
| Q34723758 | Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? |
| Q48476845 | Clinical dimensions of fibromyalgia symptoms and development of a combined index of severity: the CODI index. |
| Q33490837 | Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol |
| Q43088139 | Correction: Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study). |
| Q48055948 | Corrigendum to: "Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: A randomized controlled superiority trial" [Eur. Neuropsychopharmacol. 23(2013)1057-1066]. |
| Q38876474 | Cost-Utility of Group Acceptance and Commitment Therapy for Fibromyalgia Versus Recommended Drugs: An Economic Analysis Alongside a 6-Month Randomized Controlled Trial Conducted in Spain (EFFIGACT Study). |
| Q34947318 | Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study). |
| Q35380186 | Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study) |
| Q35938110 | Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). |
| Q46589078 | Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial. |
| Q34374726 | Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. |
| Q51910373 | Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. |
| Q48911703 | Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial. |
| Q41075626 | Functional Status, Quality of Life, and Costs Associated With Fibromyalgia Subgroups: A Latent Profile Analysis. |
| Q36035193 | Impact of IPDE-SQ personality disorders on the healthcare and societal costs of fibromyalgia patients: a cross-sectional study. |
| Q50436405 | Impact of pharmaceutical intervention in preventing relapses in depression in Primary Care |
| Q38946930 | Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients |
| Q51853983 | Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study. |
| Q50737028 | [Do we really follow the Mediterranean diet?]. |
| Q73857125 | [Non-cardiogenic acute pulmonary edema and recurrent leukopenia caused by hydrochlorothiazide] |
| Q60728414 | ¿Cómo derivamos a salud mental desde atención primaria? |
Search more.